Last reviewed · How we verify

NCT04370002: SENSCODE

Sensor-based Characterization of Depression

Status unknown Last updated 3 November 2023
What this trial tests

trial in Unipolar Depression in 100 participants. Status unknown.

Timeline
28 January 2020
Primary endpoint
1 September 2024
30 November 2024

Quick facts

Lead sponsorMassachusetts General Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date28 January 2020
Primary completion1 September 2024
Estimated completion30 November 2024
Sites2 locations across United States

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 75, any sex, with Unipolar Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a longitudinal study where individual with Major Depressive Disorder (MDD) will be monitored for 12 weeks. The study aims to develop an objective, sensor-based, algorithm able to detect the presence of depression as well as predict treatment response. Measurement-based treatment is considered optimal and the development of a valid passive, objective, behavioral and biological assessment of depressive symptoms that does not rely on clinician interviews will improve monitoring and ultimately improve treatment significantly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Unipolar Depression

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04370002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing